title: The polymorphism rs763780 in the IL-17F gene is associated with response to biological drugs in patients with psoriasis.
abstract: Psoriasis improves when IL-17 is blocked. Anti-TNF drugs reduce the IL-17 signaling pathway, and anti-IL-17 drugs are being developed to treat moderate-to-severe psoriasis. We analyzed three SNPs in IL-17A (rs2275913 and rs10484879) and IL-17F (rs763780) to look for an association with psoriasis and/or with response to anti-TNF drugs or ustekinumab. We included 197 healthy controls and 194 patients with moderate-to-severe psoriasis. The results of the univariate analysis showed an association between rs10484879 and psoriasis, although this relationship disappeared after adjustment for HLA-C (rs12191877). We also found an association between rs763780 (IL-17F) and response to ustekinumab (n = 70) and infliximab (n = 37) at 3 and 6 months and an association between rs763780 and the response to adalimumab at 6 months (n = 67).
authors.affiliation: Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, University Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain.
authors.forename: Rocío
authors.initials: R
authors.lastname: Prieto-Pérez
authors.affiliation: Dermatology Service, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain.
authors.forename: Guillermo
authors.initials: G
authors.lastname: Solano-López
authors.affiliation: Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, University Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain.|Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.
authors.forename: Teresa
authors.initials: T
authors.lastname: Cabaleiro
authors.affiliation: Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, University Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain.
authors.forename: Manuel
authors.initials: M
authors.lastname: Román
authors.affiliation: Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, University Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain.
authors.forename: Dolores
authors.initials: D
authors.lastname: Ochoa
authors.affiliation: Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, University Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain.
authors.forename: María
authors.initials: M
authors.lastname: Talegón
authors.affiliation: Dermatology Service, Hospital Universitario Gregorio Marañón, 28007 Madrid, Spain.
authors.forename: Ofelia
authors.initials: O
authors.lastname: Baniandrés
authors.affiliation: Dermatology Service, Hospital Universitario Fundación Alcorcón, 28922 Alcorcón, Madrid, Spain.
authors.forename: José Luis
authors.initials: JL
authors.lastname: López Estebaranz
authors.affiliation: Dermatology Service, Hospital Universitario Infanta Leonor, 28031 Madrid, Spain.
authors.forename: Pablo
authors.initials: P
authors.lastname: de la Cueva
authors.affiliation: Dermatology Service, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain.
authors.forename: Esteban
authors.initials: E
authors.lastname: Daudén
authors.affiliation: Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, University Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain.|Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.
authors.forename: Francisco
authors.initials: F
authors.lastname: Abad-Santos
mesh_terms: D000293:Adolescent; D000328:Adult; D044466:Asian People; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D015236:HLA-C Antigens / Q000235:genetics; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use; D020381:Interleukin-17 / Q000235:genetics*; D008297:Male; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D011565:Psoriasis / Q000188:drug therapy* / Q000235:genetics*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D000069549:Ustekinumab / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D015236:HLA-C Antigens; C440021:IL17F protein, human; D020381:Interleukin-17; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000069549:Ustekinumab
keywords: IL-17; adalimumab; etanercept; infliximab; pharmacogenetics; psoriasis; rs10484879; rs2275913; rs763780; ustekinumab